Eugene Swenson

Statistics

Publications

Citations

1.8K

H-Index

Active since

1992

Affiliations

Bristol-Myers Squibb (United States)(Current)

Texas Liver Institute

The University of Texas at San Antonio Health Science Center

Pfizer (United States)

Assistance Publique – Hôpitaux de Paris

Eugene Swenson is an author at Bristol-Myers Squibb (United States) specializing in combination antiviral regimens, viral hepatitis, and antiviral therapy.

ORCID

Publications per year

1992–2023

Publications

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

Fred Poordad, Eugene R. Schiff, John M. Vierling et al. · Hepatology · 2016 · 459 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Eugene Swenson, William Curatolo · Advanced Drug Delivery Reviews · 1992 · 312 citations

Computing, Computer Science, Computer Security +5

Intestinal Permeability Enhancement: Efficacy, Acute Local Toxicity, and Reversibility

Eugene Swenson, William B. Milisen, William Curatolo · Pharmaceutical Research · 1994 · 250 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Éric Rondeau, Marie Scully, Gema Ariceta et al. · Kidney International · 2020 · 219 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis

Andrew J. Muir, Fred Poordad, Jacob Lalezari et al. · JAMA · 2015 · 126 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

1–5 of 14